Our results further support that tEVs disrupt normal bone marrow cell development and induce an imbalance between B lymphocytes and myeloid cells, indicating that RAB1A may serve as a novel therapeutic target for PCa treatment. This evidence concerns the gene RAB1A and posterior cortical atrophy.